medigraphic.com
ISSN 1405-1710 (Print)

2013, Number 2

<< Back Next >>

Rev Cent Dermatol Pascua 2013; 22 (2)

Psoriasis and metabolic syndrome

Jurado SF, Peralta CG, Morales SM, Rodríguez AM, Peralta PML

Language: Spanish
References: 34
Page: 50-55
PDF size: 186.64 Kb.


ABSTRACT

Psoriasis is an inflammatory, chronic dermatoses, in whose pathogenesis is involved the immunologic system. A previous meta-analysis test demonstrated that patients with psoriasis have the double of risk of developing metabolic syndrome that the population in general. Studies do not exist in Mexican population. Objective: To determine the prevalence of metabolic syndrome in patients with psoriasis. Material and methods: Patients were recluted by clinical and histophatological diagnosis of psoriasis. They were evaluated clinical and it decided if they had metabolic syndrome in agreement to the criteria of the NCEP ATP III. The extension and severity of the dermatoses were evaluated with the test area PASI. Results: Thirty nine patients with psoriasis in plates were studied from the external consultation of the Dermatologic Center «Dr. Ladislao de la Pascua», 43.5% of them (IC95%, 28-60%) with metabolic syndrome. When patients compared with and without metabolic syndrome, we found statistically significant differences in the abdominal circumference, level of triglycerides and systemic blood pressure (p ‹ 0.05). Conclusions: Due to the size of the sample and his homogeneity in relation to the characteristics of the psoriasis, it was not possible to determine accurately the prevalence of the metabolic syndrome in Mexican population. This study will serve as precedent for other epidemiological tests that explore this association.


REFERENCES

  1. Griffi ths CEM, Barker JNWN. Pathogenesis and clinical features of psoriasis. Lancet. 2007; 9583: 263-71.

  2. Griffi ths CEM. The immunological basis of psoriasis. JEADV. 2003; 17(s2): 1-5.

  3. Parisi R, Symmons D, Griffi ths C, Ashcroft D. Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence. J Invest Dermatol. 2013;133:377-385.

  4. Icen M, Crowson CS, McEvoy MT, Dann FJ, Gabriel SE, Kremers HM. Trends in incidence of adult-onset psoriasis overt three decades: a population-based study. J Am Acad Dermatol. 2009;60:394-401.

  5. Gelfand JM, Weinstein R, Porter SB et al. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005;141:1537-41.

  6. Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmunity. 2010;34:J314-J321.

  7. Samarasekera EJ, Neilson JM, Warren RB, Parnham J, Smith CH. Incidence of cardiovascular disease in people with psoriasis: a systematic review and meta-analysis. J Invest Dermatol. 2013. doi: 10.1038/jid.2013.149.

  8. Khalid U, Hansen PR, Gislason GH, Lindhardsen J, Kristensen SL, Winther SA, Skov L, Torp-Pedersen C, Ahlehoff O. Psoriasis and New-Onset Diabetes Mellitus: A Danish nationwide cohort study. Diabetes Care. 2013;36:2402-7. doi: 10.2337/dc12-2330.

  9. Armstrong AW, Harskamp CT, Armstrong EJ et al. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2013;68:654-662.

  10. Grundy SM, Brewer B, Cleeman JI et al. Defi nition of metabolic syndrome. Report of the National Heart, Lung, and Blood Institute/ American Heart Association Conference on scientifi c issues related to defi nition. Circulation. 2004;109:433-438.

  11. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome. An American Hearth Association/National Heart, Lung, and Blood Institute Scientifi c Statement. Circulation. 2005;112:2735-2752.

  12. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome: a new worldwide defi nition. Lancet. 2005;366:1059-1062.

  13. Ford ES. Prevalence of the metabolic síndrome defi ned by the International Diabetes Federation among adults in the U.S. Diabetes Care. 2005;28:2745-2749.

  14. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. Findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-359.

  15. Rojas R, Aguilar-Salinas CA, Jiménez-Corona A et al. Metabolic syndrome in Mexican adults. Results from the National Health and Nutrition Survey 2006. Salud Pública Mex. 2010;52(supl 1):S11-S18.

  16. Mallbris L, Ritchlin CT, Stahle M. Metabolic disorders in patients with psoriasis and psoriatic arthritis. Curr Rheumatol Rep. 2006;8:355-363.

  17. Sommer D, Jenisch S, Suchan M et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006; 298:321-328.

  18. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2013;68:654-662.

  19. Nickoloff BJ, Karabin GD, Barker JN et al. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol. 1991;138:129-40.

  20. Chen YJ, Wu CY, Shen JL et al. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol. 2008;144: 1571-1575.

  21. Márquez-Sandoval F, Macedo-Ojeda G, Viramontes-Hörner D et al. The prevalence of metabolic syndrome in Latin America: a systematic review. Public Health Nutrition. 2011;14:1702-1713.

  22. Aguilar-Salinas CA, Rojas R, GómezPérez FJ et al. High prevalence of metabolic syndrome in Mexico. Arch Med Res. 2004;35:76-81.

  23. Gisondi P, Tessari G, Conti A et al. Prevalence of metabolic syndrome in patients whit psoriasis: a hospital-based case-control study. Br J Dermatol. 2007; 157: 68-73.

  24. Nisa N, Qazi MA. Prevalence of metabolic syndrome in patients with psoriasis. Indian J Dermatol venereal Leprol. 2010; 76:662-5.

  25. Love TJ, Qureshi AA, Karlson EW et al. Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006. Arch Dermatol. 2011;147:419-424.

  26. Chen YJ, Wu CY, Shen JL et al. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol. 2008;144:1571-1575.

  27. Al-Mutiari N, Al-Farag S, Al-Mutiari A et al. Comorbidities associated with psoriasis: an experience from the Middle East. J Dermatol. 2010;37:146-55.

  28. Lisi D, Macaione F, Corrado E et al. Cardiovascular risk profi le of patients with psoriasis. Recenti Prog Med. 2013; 104:102-105.

  29. Mebazaa A, El-Asmi M, Zidi W et al. Metabolic syndrome in Tunisian psoriatic patients: prevalence and determinants. JEADV. 2011;25:705-709.

  30. Langan SM, Seminara NM, Shin DB et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol. 2012;132(3 pt 1):556-562.

  31. Topic I, Simic D. Prevalence of metabolic syndrome in patients with psoriasis at Mostar Clinical Hospital. Acta Clin Croat. 2013;52:53-58.

  32. Madanagobalane S, Anandan S. Prevalence of metabolicsyndrome in South Indian patients with psoriasis vulgaris and the relation between disease severity and metabolicsyndrome: a hospital-based case-control study. Indian J Dermatol. 2012;57:353:357.

  33. Zindaci I, Albayrak O, Kavala M et al. Prevalence of metabolic syndrome in patients with psoriasis. Scientifi c World Journal. 2012;:312463. doi: 10.1100/2012/312463.

  34. Augustin M, Reich K, Glaeske G et al. Co-morbidity and age-related prevalence of psoriasis: Analysis of health insurance data in Germany. Acta Derm Venereol. 2010;90:147-151.




2020     |     www.medigraphic.com